Measuring Clinical Treatment Response in Myasthenia Gravis.
Measuring Clinical Treatment Response in Myasthenia Gravis.
复制标题
DOI:
10.1016/j.ncl.2018.01.006
复制
发表时间:
2018-05
影响因子:
2.4
通讯作者:
Barohn RJ
中科院分区:
文献类型:
--
作者:
Barnett C;Herbelin L;Dimachkie MM;Barohn RJ
There are several aspects of health that can be measured, and these represent different aspects of the disease, from the pathophysiology (eg, antibody titers), to the symptoms and signs, to the effect on the individual and their relation to society. 1 Because different outcome measures are aimed at different aspects of the disease process, it is fundamental to understand what a given tool measures, as well as for which purpose it was developed and in which population it was tested. One way to understand these different aspects of the disease is through the International Classification of Functioning, Disability and Health (ICF), 2 published by the World Health Organization. The ICF identifies 3 major ways in which a disease or injury affects in individual: impairments of body function or structures, which are basically the signs and symptoms; activity limitations, which are the effects of the disease and its symptoms on activities of daily life; and participation limitations, which are the effects on a patient’s social interactions, such as looking for work or caring for their family. Additionally, these aspects of the disease are also affected by personal and environmental factors (eg, social support, cultural factors, and accessibility). Disability is—according to the ICF—the interaction between symptoms, activities, and participation restrictions and personal and environmental factors. 2 Health-related quality of life (HRQoL) goes beyond the concept of disability and it is, by definition, a subjective and multidimensional concept, including physical functioning, mental or psychological well-being, occupational status, and social interactions. 3 The impairments of body functions/structures are thought to be less affected by social and environmental factors and, therefore, are typically considered to reflect more directly disease severity. This factor is why most outcome measures aimed at quantifying disease severity capture the signs and symptoms, whereas measures focused on
登录
查看更多内容
DOI:
10.1111/j.1749-6632.2012.06771.x
发表时间:
2012-01-01
期刊:
MYASTHENIA GRAVIS AND RELATED DISORDERS I
影响因子:
--
作者:
Baggi, Fulvio;Mantegazza, Renato;Sanders, Donald
通讯作者:
Sanders, Donald
影响因子:
3.4
作者:
Farrugia, Maria E.;Harle, Heather D.;Burns, Ted M.
通讯作者:
Burns, Ted M.
影响因子:
11
作者:
Barnett, Carolina;Wilson, Graham;Bril, Vera
通讯作者:
Bril, Vera
DOI:
10.1111/j.1749-6632.1998.tb11015.x
发表时间:
1998-01-01
期刊:
MYASTHENIA GRAVIS AND RELATED DISEASES
影响因子:
--
作者:
Barohn, RJ;McIntire, D;Bryan, WW
通讯作者:
Bryan, WW
影响因子:
9.9
作者:
Burns, Ted M.;Conaway, Mark;Sanders, Donald B.
通讯作者:
Sanders, Donald B.